Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia

Clinical and Applied Thrombosis/Hemostasis

Volumn 10, Issue 2, 2004, Pages 89-126

  Öztürk, M Akif ^a,c   Haznedaroǧlu, Ibrahim C ^b   Turgut, Mehmet ^b   Göker, Hakan ^b  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Antiphospholipid antibody syndrome; Clinical features; Laboratory investigation; Lupus anticoagulants; Management; Pathobiology; Terminology

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; ANTICOAGULANT AGENT; ANTIOXIDANT; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CHLOROQUINE; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DALTEPARIN; DANAZOL; DAPSONE; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LJP 1082; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PREDNISONE; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; STEROID; UNCLASSIFIED DRUG; WARFARIN;

ANTIBODY DETECTION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS WASTAGE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; IMMUNOASSAY; INFECTION; KIDNEY DISEASE; LOW DRUG DOSE; LUNG DISEASE; NOMENCLATURE; OSTEOPOROSIS; PATHOGENESIS; PLASMAPHERESIS; PREGNANCY COMPLICATION; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SKIN DEFECT; SPONTANEOUS ABORTION; SYSTEMIC DISEASE; TERMINAL DISEASE; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; THROMBOPHILIA;

EID: 1842863095     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960401000201     Document Type: Review

References (385)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752.
2. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: An analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost 1999;81:929.
3. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544.
4. Bevers EM, Galli M, Barbui T, et al. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629.
5. Roubey RA, Pratt CW, Buyon JP, et al. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992;90:1100.
6. Oosting JD, Derksen RH, Entjes HT, et al. Lupus anticoagulant activity is frequently dependent on the presence of beta2-glycoprotein I. Thromb Haemost 1992;67:499.
7. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854.
8. Roubey RA, Eisenberg RA, Harper MF, et al. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995;154:954.
9. Matsuura E, Igarashi Y, Yasuda T, et al. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457.
10. Sheng Y, Kandiah DA, Krilis SA. Anti-beta 2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glycoprotein I with low affinity: Dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity. J Immunol 1998;161:2038.
11. Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995;73:29.
12. Chamley LW, Duncalf AM, Konarkowska B, et al. Conformationally altered beta 2-glycoprotein I is the antigen for anti-cardiolipin antibodies. Clin Exp Immunol 1999;11:571.
13. 2-glycoprotein I? Arthritis Rheum 2003;48:2111.
14. Harris EN, Loizou S, Englert H, et al. Anticardiolipin antibodies and lupus anticoagulant. Lancet 1984;ii:1099.
15. Triplett DA, Brandt JT, Musgrave KA, et al. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988;259:550.
16. Alving BM, Barr CF, Tang DB. Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times. Am J Med 1990;88:112.
17. Cabral AR, Amigo MC, Cabiedes J, et al. The antiphospholipid/cofactor syndromes: A primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996;101:472.
18. Bick RL. Antiphospholipid thrombosis syndromes. Hematol Oncol Clin North Am 2003;17:115.
19. Gilman-Sachs A, Lubinski J, Beer AE, et al. Patterns of anti-phospholipid antibody specificities. J Clin Lab Immunol 1991;35:83.
20. Silver RM, Pierangeli SS, Edwin SS, et al. Pathogenic antibodies in women with obstetric features of antiphospholipid syndrome who have negative test results for lupus anticoagulant and anticardiolipin antibodies. Am J Obstet Gynecol 1997;176:628.
21. Merrill JT. Which antiphospholipid antibody tests are most useful? Rheum Dis Clin North Am 2001;27:525.
22. Gomez-Pacheco L, Villa AR, Drenkard C, et al. Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 1999;106:417.
23. Cervera R, Piette JC, Font J, et al. Euro-Phospholipid Project Group. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019.
24. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990;112:682.
25. Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353.
26. Bick RL. Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost 2001;7:241.
27. Bick RL, Arun B, Frenkel EP. Antiphospholipid-thrombosis syndromes. Haemostasis 1999;29:100.
28. Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 1999;25:333.
29. Levine SR, Deegan MJ, Futrell N, et al. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990;40:1181.
30. Hunt JE, McNeil HP, Morgan GJ, et al. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992;1:75.
31. Guglielmone H, Vitozzi S, Elbarcha O, et al. Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections. Ann Rheum Dis 2001;60:500.
32. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003;62:388.
33. Uthman I, Tabbarah Z, Gharavi AE. Hughes syndrome associated with cytomegalovirus infection. Lupus 1999;8:775.
34. Labarca JA, Rabaggliati RM, Radrigan FJ, et al. Antiphospholipid syndrome associated with cytomegalovirus infection: Case report and review. Clin Infect Dis 1997;24:197.
35. Constans J, Guerin V, Couchouron A, et al. Autoantibodies directed against phospholipids or human beta 2-glycoprotein I in HIV-seropositive patients: Relationship with endothelial activation and antimalonic dialdehyde antibodies. Eur J Clin Invest 1998;28:115.
36. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002;31:256.
37. Guzman J, Cabral AR, Cabiedes J, et al. Antiphospholipid antibodies in patients with idiopathic autoimmune haemolytic anemia. Autoimmunity 1994;18:51.
38. Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002;90:29.
39. Inanc M, Donohoe S, Ravirajan CT, et al. Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br J Rheumatol 1998;37:1089.
40. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry. Am J Med 1996;100:530.
41. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997.
42. Antiphospholipid Antibodies in Stroke Study Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 1993;43:2069.
43. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23.
44. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997;28:1660.
45. Levine SR, Brey RL, Sawaya KL, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995;38:119.
46. Abu-Shakra M, Gladman DD, Urowitz MB, et al. Anticardiolipin antibodies in systemic lupus erythematosus: Clinical and laboratory correlations. Am J Med 1995;99:624.
47. Branch DW, Dudley DJ, Mitchell MD. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in Balb/c mice: A model for autoimmune fetal loss. Am J Obstet Gynecol 1990;163:210.
48. Piona A, Larosa L, Tincani A, et al. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice. Scand J Immunol 1995;41:427.
49. Blank M, Cohen J, Toder V, et al. Induction of antiphospholipid syndrome in naive mice with mouse monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci USA 1991;88:3069.
50. Blank M, Tincani A, Shoenfeld Y. Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies. J Rheumatol 1994;21:100.
51. Suzuki T, Takabayashi K, Ichikawa K, et al. Effects of monoclonal anticardiolipin antibody in pregnant mice. J Rheumatol 1996;23:83.
52. Pierangeli SS, Barker JH, Stikovac D, et al. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost 1994;71:670.
53. Pierangeli SS, Liu X, Barker JH, et al. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995;74:1361.
54. Rosove MH, Brewer PM. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303.
55. Polz E, Kostner GM. The binding of beta 2-glycoprotein-I to human serum lipoproteins: Distribution among density fractions. FEBS Lett 1979;102:183.
56. Chonn A, Semple SC, Cullis PR. Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. J Biol Chem 1995;270:25845.
57. Manfredi AA, Rovere P, Heltai S, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum 1998;41:215.
58. Balasubramanian K, Schroit AJ. Characterization of phosphatidylserine-dependent beta2-glycoprotein I macrophage interactions. Implications for apoptotic cell clearance by phagocytes. J Biol Chem 1998;273:29272.
59. Brighton TA, Hogg PJ, Dai YP, et al. Beta 2-glycoprotein I in thrombosis: Evidence for a role as a natural anticoagulant. Br J Haematol 1996;93:185.
60. Nimpf J, Bevers EM, Bomans PH, et al. Prothrombinase activity of human platelets is inhibited by beta2-glycoprotein-I. Biochim Biophys Acta 1986;884:142.
61. Nimpf J, Wurm H, Kostner GM. Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987;63:109.
62. Henry ML, Everson B, Ratnoff OD. Inhibition of the activation of Hageman factor (factor XII) by beta2-glycoprotein I. J Lab Clin Med 1988;111:519.
63. Schousboe I. beta 2-Glycoprotein I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985;66:1086.
64. Merrill JT, Zhang HW, Shen C, et al. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 1999;81:748.
65. Ieko M, Yasukouchi T, Sawada KI, et al. The influence of beta2-glycoprotein I on tissue factor activity. Semin Thromb Hemost 1998;24:211.
66. Bancsi LF, van der Linden IK, Bertina RM. Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992;67:649.
67. Arnout J. Antiphospholipid syndrome: Diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001;86:83.
68. Angles-Cano E, Guillin MC. Antiphospholipid antibodies and the coagulation cascade. Rheum Dis Clin North Am 2001;27:573.
69. Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997;337:154.
70. Rand JH, Wu XX, Andree HA, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A "lupus procoagulant" phenomenon. Blood 1998;92:1652.
71. Hanly JG, Smith SA. Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol 2000;120:537.
72. Bevers EM, Janssen MP, Willems GM, et al. No evidence for enhanced thrombin formation through displacement of annexin V by antiphospholipid antibodies. Thromb Haemost 2000;83:792.
73. Willems GM, Janssen MP, Comfurius P, et al. Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membranes. Biochemistry 2000;39:1982.
74. Esmon CT. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway. J Autoimmun 2000;15:113.
75. Dizon-Townson D, Hutchison C, Silver R, et al. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost 1995;74:1029.
76. Crowther MA, Johnston M, Weitz J, Ginsberg JS. Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemost 1996;76:689.
77. Ames PR, Tommasino C, Iannaccone L, et al. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - a crucial role for acquired free protein S deficiency. Thromb Haemost 1996;76:190.
78. Borrell M, Sala N, de Castellarnau C, et al. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992;68:268.
79. Malia RG, Kitchen S, Greaves M, et al. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990;76:101.
80. Nojima J, Kuratsune H, Suehisa E, et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002;118:577.
81. Tsakiris DA, Settas L, Makris PE, et al. Lupus anticoagulant - antiphospholipid antibodies and thrombophilia. Relation to protein C - protein S - thrombomodulin. J Rheumatol 1990;17:785.
82. Bokarewa MI, Blomback M, Egberg N, et al. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 1994;5:37.
83. Cariou R, Tobelem G, Bellucci S, et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells - inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988;60:54.
84. Gennari L, Blanco A, Alberto MF, et al. The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein antibodies could be associated with acquired activated protein C resistance in non-systemic lupus erythematosus patients. Br J Haematol 2003;121:527.
85. Hwang KK, Yang CD, Yan W, et al. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003;48:1622.
86. Matsuda J, Gohchi K, Kawasugi K, et al. Inhibitory activity of anti-beta 2-glycoprotein I antibody on factor Va degradation by activated-protein C and its cofactor protein S. Am J Hematol 1995;49:89.
87. Atsumi T, Khamashta MA, Amengual O, et al. Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): A possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol 1998;112:325.
88. Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism? Blood 1993;81:2618.
89. Carson CW, Comp PC, Rezaie AR, et al. Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis. J Rheumatol 2000;27:384.
90. de Groot PG, Horbach DA, Derksen RH. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: Relation to the pathogenesis of thrombosis. Lupus 1996;5:488.
91. Field SL, Brighton TA, McNeil HP, et al. Recent insights into antiphospholipid antibody-mediated thrombosis. Baillieres Best Pract Res Clin Haematol 1999;12:407.
92. Smirnov MD, Triplett DT, Comp PC, et al. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995;95:309.
93. Esmon NL, Safa O, Smirnov MD, et al. Antiphospholipid antibodies and the protein C pathway. J Autoimmun 2000;15:221.
94. Carreras LO, Vermylen JG. "Lupus" anticoagulant and thrombosis - possible role of inhibition of prostacyclin formation. Thromb Haemost 1982;48:38.
95. Lellouche F, Martinuzzo M, Said P, et al. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991;78:2894.
96. Nakamura N, Shidara Y, Kawaguchi N, et al. Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: Involvement of annexin V. Biochem Biophys Res Commun 1994;205:1488.
97. Nakamura N, Ban T, Yamaji K, et al. Localization of the apoptosis -inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. J Clin Invest 1998;101:1951.
98. Bombeli T, Karsan A, Tait JF, et al. Apoptotic vascular endothelial cells become procoagulant. Blood 1997;89:2429.
99. Cho CS, Cho ML, Chen PP, et al. Antiphospholipid anti-bodies induce monocyte chemoattractant protein-1 in endothelial cells. J Immunol 2002;168:4209.
100. Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I anti-bodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997;40:551.
101. Del Papa N, Guidali L, Spatola L, et al. Relationship between anti-phospholipid and anti-endothelial cell anti-bodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 1995;13:179.
102. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211.
103. George J, Blank M, Levy Y, et al. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998;97:900.
104. Pierangeli SS, Colden-Stanfield M, Liu X, et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997.
105. Kaplanski G, Cacoub P, Farnarier C, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis. Arthritis Rheum 2000;43:55.
106. Pierangeli SS, Gharavi AE, Harris EN. Experimental thrombosis and antiphospholipid antibodies: New insights. J Autoimmun 2000;15:241.
107. Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997;78:759.
108. Amengual O, Atsumi T, Khamashta MA, et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276.
109. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: A pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997;40:834.
110. Dobado-Berrios PM, Lopez-Pedrera C, Velasco F, et al. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999;82:1578.
111. Kornberg A, Renaudineau Y, Blank M, et al. Anti-beta 2-glycoprotein I antibodies and anti-endothelial cell anti-bodies induce tissue factor in endothelial cells. Isr Med Assoc J 2000;2 Suppl:27.
112. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol 1993;168:206.
113. Kornberg A, Blank M, Kaufman S, et al. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153:1328.
114. Salemink I, Blezer R, Willems GM, et al. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 2000;84:653.
115. Adams MJ, Donohoe S, Mackie IJ, et al. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. Br J Haematol 2001;114:375.
116. Marcus DM, Schwarting GA. Immunochemical properties of glycolipids and phospholipids. Adv Immunol 1976;23:203.
117. Gharavi AE, Sammaritano LR, Wen J, et al. Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest 1992;90:1105.
118. Gharavi AE, Sammaritano LR, Bovastro JL Jr, et al. Specificities and characteristics of beta 2 glycoprotein I-induced antiphospholipid antibodies. J Lab Clin Med 1995;125:775.
119. Blank M, Faden D, Tincani A, et al. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994;7:441.
120. Garcia CO, Kanbour-Shakir A, Tang H, et al. Induction of experimental antiphospholipid syndrome in PL/J mice following immunization with beta2 GPI. Am J Reprod Immunol 1997;37:118.
121. Gharavi AE, Pierangeli SS, Colden-Stanfield M, et al. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 1999;163:2922.
122. Gharavi EE, Chaimovich H, Cucurull E, et al. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus 1999;8:449.
123. Gharavi AE, Pierangeli SS, Espinola RG, et al. Anti-phospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002;46:545.
124. Gharavi AE, Pierangeli SS, Harris EN. Origin of antiphospholipid antibodies. Rheum Dis Clin North Am 2001;27:551.
125. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003;1:931.
126. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 1983;736:57.
127. Price BE, Rauch J, Shia MA, et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol 1996;157:2201.
128. Sorice M, Circella A, Misasi R, et al. Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipids antibodies. Clin Exp Immunol 2000;122:277.
129. Manfredi AA, Rovere P, Galati G, et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998;41:205.
130. Levine JS, Subang R, Koh JS, et al. Induction of antiphospholipid autoantibodies by beta2-glycoprotein I bound to apoptotic thymocytes. J Autoimmun 1998;11:413.
131. Subang R, Levine JS, Janoff AS, et al. Phospholipid-bound beta 2-glycoprotein I induces the production of anti-phospholipid antibodies. J Autoimmun 2000;15:21,
132. Pittoni V, Ravirajan CT, Donohoe S, et al. Human monoclonal anti-phospholipid antibodies selectively bind to membrane phospholipid and beta2-glycoprotein I (beta2-GPI) on apoptotic cells. Clin Exp Immunol 2000;119:533.
133. Rauch J, Subang R, D'Agnillo P, et al. Apoptosis and the antiphospholipid syndrome. J Autoimmun 2000;15:231.
134. Horkko S, Miller E, Dudl E, et al. Antiphospholipid anti-bodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996;98:815.
135. Horkko S, Miller E, Branch DW, et al. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc Natl Acad Sci USA 1997;94:10356.
136. Fabisiak JP, Kagan VE, Ritov VB, et al. Bcl-2 inhibits selective oxidation and externalization of phosphatidylserine during paraquat-induced apoptosis. Am J Physiol 1997;272 (2 Pt 1):C675.
137. Hockenbery DM, Oltvai ZN, Yin XM, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241.
138. Vazquez-Mellado J, Llorente L, Richaud-Patin Y, et al. Exposure of anionic phospholipids upon platelet activation permits binding of beta 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmun 1994;7:335.
139. Shi W, Chong BH, Chesterman CN. β2-Glycoprotein-I is a requirement for anticardiolipin antibodies binding to activated platelets: Differences with lupus anticoagulants. Blood 1993;81:1255.
140. Martinuzzo ME, Maclouf J, Carreras LO, et al. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993;70:667.
141. Reverter JC, Tassies D, Escolar G, et al. Effect of plasma from patients with primary antiphospholipid syndrome on platelet function in a collagen rich perfusion system. Thromb Haemost 1995;73:132.
142. Campbell AL, Pierangeli SS, Wellhausen S, et al. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995;73:529.
143. Arvieux J, Roussel B, Pouzol P, et al. Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I. Thromb Haemost 1993;70:336.
144. Nojima J, Suehisa E, Kuratsune H, et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus - possible association with thrombotic and thrombocytopenic complications. Thromb Haemost 1999;81:436.
145. Wiener MH, Burke M, Fried M, et al. Thromboagglutination by anticardiolipin antibody complex in the antiphospholipid syndrome: A possible mechanism of immune-mediated thrombosis. Thromb Res 2001;103:193.
146. Emmi L, Bergamini C, Spinelli A, et al. Possible pathogenetic role of activated platelets in the primary antiphospholipid syndrome involving the central nervous system. Ann NY Acad Sci 1997;823:188.
147. Ford I, Urbaniak S, Greaves M. IgG from patients with antiphospholipid syndrome binds to platelets without induction of platelet activation. Br J Haematol 1998;102:841.
148. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;353:1348.
149. Godeau B, Piette JC, Fromont P, et al. Specific anti-platelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997;98:873.
150. Macchi L, Rispal P, Clofent-Sanchez G, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid-antibody. syndrome: Their relationship with the observed thrombocytopenia. Br J Haematol 1997;98:336.
151. Arnout J. The pathogenesis of the antiphospholipid syndrome: A hypothesis based on parellelism with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75:536.
152. Walenga JM, Michal K, Hoppensteadt D, et al. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost 1999;5 Suppl 1:S76.
153. Jankowski M, Vreys I, Wittevrongel C, et al. Thrombogenicity of beta-2-glycoprotein I dependent antiphospholipid antibodies in a photochemically induced thrombosis in the hamster. Blood 2003;101:157.
154. Lockwood CJ, Rand JH. The immunobiology and obstetrical consequences of antiphospholipid antibodies. Obstet Gynecol Surv 1994;49:432.
155. Out HJ, Kooijman CD, Bruinse HW, et al. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991;41:179.
156. Krikun G, Lockwood CJ, Wu XX, et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: Immunolocalization and in vitro regulation. Placenta 1994;15:601.
157. Wang X, Campos B, Kaetzel MA, et al. Annexin V is critical in the maintenance of murine placental integrity. Am J Obstet Gynecol 1999;180:1008.
158. Rand JH, Wu XX, Guller S, et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994;171:1566.
159. Rote NS, Vogt E, DeVere G, et al. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am J Reprod Immunol 1998;39:125.
160. Lakasing L, Campa JS, Poston R, et al. Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndrome. Am J Obstet Gynecol 1999;181:180.
161. Luzzana C, Gerosa M, Riboldi P, et al. Up-date on the antiphospholipid syndrome. J Nephrol 2002;15:342.
162. Di Simone N, De Carolis S, Lanzone A, et al. In vitro effect of antiphospholipid antibody-containing sera on basal and gonadotrophin releasing hormone-dependent human chorionic gonadotrophin release by cultured trophoblast cells. Placenta 1995;16:75.
163. Di Simone N, Castellani R, Caliandro D, et al. Monoclonal anti-annexin V antibody inhibits trophoblast gonadotropin secretion and induces syncytiotrophoblast apoptosis. Biol Reprod 2001;65:1766.
164. Di Simone N, Meroni PL, del Papa N, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000;43:140.
165. Zhou Y, Fisher SJ, Janatpour M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997;99:2139.
166. Sueoka K, Shiokawa S, Miyazaki T, et al. Integrins and reproductive physiology: Expression and modulation in fertilization, embryogenesis, and implantation. Fertil Steril 1997;67:799.
167. Di Simone N, Castellani R, Caliandro D, et al. Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules. Fertil Steril 2002;77:805.
168. Hellan M, Kuhnel E, Speiser W, et al. Familial lupus anticoagulant: A case report and review of the literature. Blood Coagul Fibrinolysis 1998;9:195.
169. Atsumi T, Tsutsumi A, Amengual O, et al. Correlation between beta2-glycoprotein I valine/leucine247 polymorphism and anti-beta2-glycoproteinI antibodies in patients with primary antiphospholipid syndrome. Rheumatology 1999;38:721.
170. Hirose N, Williams R, Alberts AR, et al. A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum 1999;42:1655.
171. Asherson RA, Doherty DG, Vergani D, et al. Major histocompatibility complex associations with primary antiphospholipid syndrome. Arthritis Rheum 1992;35:124.
172. Vargas-Alarcon G, Granados J, Bekker C, et al. Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients. Arthritis Rheum 1995;38:1340.
173. Camps MT, Cuadrado MJ, Ocon P, et al. Association between HLA class II antigens and primary antiphospholipid syndrome from the south of Spain. Lupus 1995;4:51.
174. Goldstein R, Moulds JM, Smith CD, et al. MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1996;23:1173.
175. Granados J, Vargas-Alarcon G, Drenkard C, et al. Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE). Lupus 1997;6:57.
176. de Pablo P, Ramirez A, Cortina E, et al. Increased fibrin polymerization rate in patients with primary antiphospholipid syndrome and systemic lupus erythematosus. Clin Appl Thromb Hemost 2003;9:221.
177. Takeuchi R, Atsumi T, Ieko M, et al. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: Possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 2002;119:781.
178. Ieko M, Ichikawa K, Atsumi T, et al. Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. Semin Thromb Hemost 2000;26:85.
179. Shibata S, Harpel PC, Gharavi A, et al. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994;83:2532.
180. Chi HS. Recent advances in the diagnosis of antiphospholipid syndrome. Int J Hematol 2002;76 Suppl 2:47.
181. Reyes H, Dearing L, Bick RL, et al. Laboratory diagnosis of antiphospholipid syndromes. Clin Lab Med 1995;15:85.
182. Bick RL. Antiphospholipid thrombosis syndromes: Etiology, pathophysiology, diagnosis and management. Int J Hematol 1997;65:193.
183. Pierangeli SS, Gharavi AE, Harris EN. Testing for antiphospholipid antibodies: Problems and solutions. Clin Obstet Gynecol 2001;44:48.
184. Abuaf N, Meyer O, Laperche S, et al. Conclusions of the first French workshop of standardization of anticardiolipin antibody determination associated with autoimmune pathology. Ann Biol Clin 1994;52:365.
185. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: A cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002;118:548.
186. Exner T, Triplett DA, Taberner D, et al. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1991;65:320.
187. Kaczor DA, Bickford NN, Triplett DA. Evaluation of different mixing study reagents and dilution effect in lupus anticoagulant testing. Am J Clin Pathol 1991;95:408.
188. Brandt JT, Triplett DA. The effect of phospholipid on the detection of lupus anticoagulants by the dilute Russell viper venom time. Arch Pathol Lab Med 1989;113:1376.
189. Gerbutavicius R, Fareed J, Messmore HL, et al. Reference ranges of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited. Clin Appl Thromb Hemost 2002;8:51.
190. Lawrie AS, Mackie IJ, Purdy G, et al. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thromb Haemost 1999;81:758.
191. Triplett DA, Brandt JT, Kaczor D, et al. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983;79:678.
192. Arnout J, Huybrechts E, Vanrusselt M, et al. A new lupus anticoagulant neutralization test based on platelet-derived vesicles. Br J Haematol 1992;80:341.
193. Triplett DA, Stocker KF, Unger GA, et al. The Textarin/Ecarin ratio: A confirmatory test for lupus anticoagulants. Thromb Haemost 1993;70:925.
194. Reber G, Roisin JP, Migaud M, et al. Comparison of a platelet neutralization procedure with a hexagonal phase phospholipid neutralization assay as confirmatory tests for the presence of lupus anticoagulants. Thromb Res 1994;73:131.
195. Chantarangkul V, Tripodi A, Arbini A, et al. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb Res 1992;67:355.
196. Galli M, Finazzi G, Bevers EM, et al. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995;86:617.
197. Pengo V, Biasiolo A, Rampazzo P, et al. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 1999;81:256.
198. Liestol S, Jacobsen EM, Wisloff F. Dilute prothrombin time-based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin. Thromb Res 2002;105:177.
199. Rooney AM, McNally T, Mackie IJ, et al. The Taipan snake venom time:a new test for lupus anticoagulant. J Clin Pathol 1994;47:497.
200. Lindhoff-Last E, Humpich M, Schmitt J, et al. MIXCONLA: A precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulant. Clin Appl Thromb Hemost 2002;8:163.
201. Exner T. Conceptions and misconceptions in testing for lupus anticoagulants. J Autoimmun 2000;15:179.
202. Lazarchick J, Kizer J. The laboratory diagnosis of lupus anticoagulants. Arch Pathol Lab Med 1989;113:177.
203. Mader R, Ziporen L, Mader R, et al. Antiphospholipid antibodies in a heterogeneous group of patients: Experience from a central laboratory. Clin Rheumatol 2002;21:386.
204. Sakakura M, Wada H, Watanabe R, et al. Coagulation tests and anti-phospholipid antibodies in patients positive for lupus anticoagulant. Clin Appl Thromb Hemost 2000;6:144.
205. Segal JB, Lehmann HP, Petri M, et al. Testing strategies for diagnosing lupus anticoagulant: Decision analysis. Am J Hematol 2002;70:195.
206. Wisloff F, Jacobsen EM, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2002;108:263.
207. Galli M, Finazzi G, Barbui T. Antiphospholipid antibodies: Predictive value of laboratory tests. Thromb Haemost 1997;78:75.
208. Galli M, Dlott J, Norbis F, et al. Lupus anticoagulants and thrombosis: Clinical association of different coagulation and immunologic tests. Thromb Haemost 2000;84:1012.
209. Wasmuth JC, Minarro D, Homrighausen A, et al. Phospholipid autoantibodies and the antiphospholipid antibody syndrome: Diagnostic accuracy of 23 methods studied by variation in ROC curves with number of clinical manifestations. Clin Chem 2002;48:1004.
210. McIntyre JA, Wagenknecht DR, Faulk WP. Antiphospholipid antibodies: Discovery, definitions, detection and disease. Prog Lipid Res 2003;42:176.
211. Helbert M, Bodger S, Cavenagh J, et al. Optimising testing for phospholipid antibodies. J Clin Pathol 2001; 54:693.
212. Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003; 42:200.
213. Brey RL, Gharavi AE, Lockshin MD. Neurologic complications of antiphospholipid antibodies. Rheum Dis Clin North Am 1993;19:833.
214. Cuadrado MJ, Hughes GR. Hughes (antiphospholipid) syndrome. Clinical features. Rheum Dis Clin North Am 2001;27:507.
215. Dunn JP, Noorily SW, Petri M, et al. Antiphospholipid antibodies and retinal vascular disease. Lupus 1996;5:313.
216. Castanon C, Amigo MC, Banales JL, et al. Ocular vasoocclusive disease in primary antiphospholipid syndrome. Ophthalmology 1995;102:256.
217. Naarendorp M, Spiera H. Sudden sensorineural hearing loss in patients with systemic lupus erythematosus or lupus-like syndromes and antiphospholipid antibodies. J Rheumatol 1998;25:589.
218. Kaplan SD, Chartash EK, Pizzarello RA, et al. Cardiac manifestations of the antiphospholipid syndrome. Am Heart J 1992;124:1331.
219. Cervera R, Khamashta MA, Font J, et al. High prevalence of significant heart valve lesions in patients with the 'primary' antiphospholipid syndrome. Lupus 1991;1:43.
220. Nayak AK, Komatireddy G. Cardiac manifestations of the antiphospholipid antibody syndrome: A review. Mo Med 2002;99:171.
221. Baker WF Jr, Bick RL. Antiphospholipid antibodies in coronary artery disease: A review. Semin Thromb Hemost 1994;20:27.
222. Kattwinkel N, Villanueva AG, Labib SB, et al. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome. Ann Intern Med 1992;116:974.
223. Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997;36:970.
224. Espinosa G, Cervera R, Font J, et al. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002;61:195.
225. Nochy D, Daugas E, Huong DL, et al. Kidney involvement in the antiphospholipid syndrome. J Autoimmun 2000;15:127.
226. Isom R, Nickolas TL, Radhakrishnan J. Nephrological and obstetric complications of the antiphospholipid syndrome. Expert Opin Investig Drugs 2002;11:819.
227. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: A prospective cohort study. Blood 2001;98:1760.
228. Espinosa G, Santos E, Cervera R, et al. Adrenal involvement in the antiphospholipid syndrome: Clinical and immunologic characteristics of 86 patients. Medicine 2003;82:106.
229. Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, et al. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: A prospective study by magnetic resonance imaging. Arthritis Rheum 2003;48:732.
230. Heilmann L, von Tempelhoff GF, Pollow K. Antiphospholipid syndrome in obstetrics. Clin Appl Thromb Hemost 2003;9:143.
231. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999; 42:1309.
232. Asherson RA. The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Lupus 1998;7 Suppl 2:S55.
233. Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Opin Hematol 2000;7:325.
234. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;ii:1211.
235. Horbach DA, Oort EV, Donders RAJM, et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Thromb Haemost 1996;76:916.
236. Tuhrim S, Rand JH, Wu XX, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999;30:1561.
237. Oger E, Lernyer C, Dueymes M, et al. Association between IgM anticardiolipin antibodies and deep venous thrombosis in patients without systemic lupus erythematosus. Lupus 1997;6:455.
238. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332.
239. Lam EY, Taylor LM Jr, Landry GJ, et al. Relationship between antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower extremity bypass operations. J Vasc Surg 2001;33:976.
240. Silver RM, Porter TF, van Leeuween I, et al. Anticardiolipin antibodies: Clinical consequences of "low titers." Obstet Gynecol 1996;87:494.
241. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003;101:1827.
242. Diri E, Cucurull E, Gharavi AE, et al. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus 1999;8:263.
243. Fanopoulos D, Teodorescu MR, Varga J, et al. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: Relationship with antiphospholipid syndrome. J Rheumatol 1998;25:675.
244. Bertolaccini ML, Atsumi T, Escudero Contreras A, et al. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001;28:2637.
245. Selva-O'Callaghan A, Ordi-Ros J, Monegal-Ferran F, et al. IgA anticardiolipin antibodies-relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost 1998;79:282.
246. Muir KW, Squire IB, Alwan W, et al. Anticardiolipin antibodies in an unselected stroke population. Lancet 1994;344:452.
247. Runchey SS, Folsom AR, Tsai MY, et al. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002;119:1005.
248. Sletnes KE, Smith P, Abdelnoor M, et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992;339:451.
249. Miret C, Cervera R, Reverter JC, et al. Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: Transient 'seronegative' antiphospholipid syndrome? Clin Exp Rheumatol 1997;15:541.
250. Carreras LO, Forastiero RR, Martinuzzo ME. Which are best biological markers of the antiphospolipid syndrome? J Autoimmun 2000;15:163.
251. Fijnheer R, Horbach DA, Donders RC, et al. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost 1996;76:514.
252. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995;86:3685.
253. Wahl DG, Guillemin F, de Maistre E, et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998;7:15.
254. Wahl DG, Guillemin F, de Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus 1997;6:467.
255. Tincani A, Spatola L, Prati E, et al. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol 1996;157:5732.
256. Forastiero RR, Martinuzzo ME, Kordich LC, et al. Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996;75:717.
257. Alarcon-Segovia D, Mestanza M, Cabiedes J, et al. The antiphospholipid/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to beta 2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. J Rheumatol 1997;24:1545.
258. Amengual O, Atsumi T, Khamashta MA, et al. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239.
259. Najmey SS, Keil LB, Adib DY, et al. The association of antibodies to beta 2 glycoprotein I with the antiphospholipid syndrome: A meta-analysis. Ann Clin Lab Sci 1997;27:41.
260. Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;22:1899.
261. Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to beta2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum 1996;39:1606.
262. McNally T, Mackie IJ, Machin SJ, et al. Increased levels of beta 2 glycoprotein-I antigen and beta 2 glycoprotein-Ibinding antibodies are associated with a history of thromboembolic complicationsin patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 1995;34:1031.
263. Previtali S, Barbui T, Galli M. Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: A case control study. Thromb Haemost 2002;88:729.
264. Detkova D, Gil-Aguado A, Lavilla P, et al. Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome? Lupus 1999;8:430.
265. Tubach F, Hayem G, Marchand JL, et al. IgG anti-beta2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: Prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 2000; 27:1437.
266. Sebastiani GD, Galeazzi M, Tincani A, et al. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999;28:344.
267. Galli M, Luciani D, Bertolini G, et al. Anti-β2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717.
268. Lee RM, Emlen W, Scott JR, et al. Anti-beta2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome. Am J Obstet Gynecol 1999;181:642.
269. Lynch A, Byers T, Emlen W, et al. Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension:a prospective study in low-risk pregnancy. Obstet Gynecol 1999;93:193.
270. Franklin RD, Hollier N, Kutteh. beta2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss. Fertil Steril 2000;73:531.
271. Audrain MA, El-Kouri D, Hamidou MA, et al. Value of autoantibodies to beta(2)-glycoprotein 1 in the diagnosis of antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:550.
272. Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J Autoimmun 2000;15:101.
273. Bajaj SP, Rapaport SI, Fierer DS, et al. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983;61:684.
274. Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed immunoelectrophoresis in patients with lupus inhibitors. Blood 1984;64:807.
275. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988;72:512.
276. Arvieux J, Darnige L, Caron C, et al. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995;74:1120.
277. Lakos G, Kiss E, Regeczy N, et al. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. J Rheumatol 2000;27:924.
278. Puurunen M, Vaarala O, Julkunen H, et al. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996;80:16.
279. Sorice M, Pittoni V, Circella A, et al. Anti-prothrombin but not "pure" anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome. Thromb Haemost 1998;80:713.
280. Bertolaccini ML, Atsumi T, Khamashta MA, et al. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 1998;25:1104.
281. Munoz-Rodriguez FJ, Reverter JC, Font J, et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica 2000;85:632.
282. Nojima J, Kuratsune H, Suehisa E, et al. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001;114:647.
283. Pengo V, Biasiolo A, Brocco T, et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996;75:721.
284. D'Angelo A, Safa O, Crippa L, et al. Relationship of lupus anticoagulant, anticardiolipin, anti-beta2-GPI and antiprothrombin autoantibodies with history of thrombosis in patients with the clinical suspicion of APA-syndrome. Thromb Haemost 1997;78:967.
285. Forastiero RR, Martinuzzo ME, Cerrato GS, et al. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997;78:1008.
286. Galli M, Beretta G, Daldossi M, et al. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997;77:486.
287. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982.
288. Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 2003;48:886.
289. Nakamura N, Kuragaki C, Shidara Y, et al. Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties. Am J Hematol 1995;49:347.
290. Satoh A, Suzuki K, Takayama E, et al. Detection of antiannexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999;26:1715.
291. Ogawa H, Zhao D, Dlott JS, et al. Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities. Am J Clin Pathol 2000;114:619.
292. Kaburaki J, Kuwana M, Yamamoto M, et al. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997; 54:209.
293. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989;86:1372.
294. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785.
295. Wu R, Lefvert AK. Autoantibodies against oxidized low density lipoproteins (oxLDL): Characterization of antibody isotype, subclass; affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol 1995;102:174.
296. Puurunen M, Manttari M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605.
297. Deguchi H, Fernandez JA, Hackeng TM, et al. Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci USA 2000;97:1743.
298. Horkko S, Olee T, Mo L, et al. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 2001;103:941.
299. Amengual O, Atsumi T, Khamashta MA, et al. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 1997; 36:964.
300. Zhao D, Ogawa H, Wang X, et al. Oxidized low-density lipoprotein and autoimmune antibodies in patients with antiphospholipid syndrome with a history of thrombosis. Am J Clin Pathol 2001;116:760.
301. Hayem G, Nicaise-Roland P, Palazzo E, et al. Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001;10:346.
302. Romero FI, Amengual O, Atsumi T, et al. Arterial disease in lupus and secondary antiphospholipid syndrome: Association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br J Rheumatol 1998;37:883.
303. Cervera R, Khamashta MA, Font J, et al. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity 1991;11:1.
304. Vismara A, Meroni PL, Tincani A, et al. Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol 1988;74:247.
305. Meroni PL, Raschi E, Testoni C, et al. Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am 2001;27:587.
306. McCrae KR, DeMichele A, Samuels P, et al. Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol 1991;79:595.
307. Sugi T, McIntyre JA. Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmun 2001;17:207.
308. Jone DW, Nicholls PJ, Donohoe S, et al. Antibodies to factor XII are distinct from antibodies to prothrombin in patients with the anti-phospholipid syndrome. Thromb Haemost 2002;87:426.
309. Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 1996;5:388.
310. Laperche S, Abuaf N, Meyer O, et al. Association of antimitochondrial antibodies type 5 and anti-beta 2 glycoprotein I antibodies in the antiphospholipid syndrome. J Rheumatol 1994;21:1678.
311. Tektonidou MG, Petrovas CA, Ioannidis JP, et al. Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. Eur J Clin Invest 2000;30:646.
312. Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol 2000;108:871.
313. Rampazzo P, Biasiolo A, Garin J, et al. Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thromb Haemost 2001;85:57.
314. Bidot CJ, Jy W, Horstman LL, Huisheng H, et al. Factor VII/VIIa: A new antigen in the anti-phospholipid antibody syndrome. Br J Haematol 2003;120:618.
315. Romero FI, Atsumi T, Tinahones FJ, et al. Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome. Arthritis Rheum 1999;42:2606.
316. Laroche P, Berard M, Rouquette AM, et al. Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Am J Clin Pathol 1996;106:549.
317. Bertolaccini ML, Roch B, Amengual O, et al. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol 1998;37:1229.
318. Harris EN, Gharavi AE, Loizou S, et al. Crossreactivity of antiphospholipid antibodies. J Clin Lab Immunol 1985;16:1.
319. Berard M, Chantome R, Marcelli A, et al. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996;23:1369.
320. Karmochkine M, Berard M, Piette JC, et al. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus. Lupus 1993;2:157.
321. Toschi V, Motta A, Castelli C, et al. Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus. Haemostasis 1993;23:275.
322. Toschi V, Motta A, Castelli C, et al. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 1998;29:1759.
323. Falcon CR, Hoffer AM, Carreras LO. Antiphosphatidylinositol antibodies as markers of the antiphospholipid syndrome. Thromb Haemost 1990;63:321.
324. Lopez-Soto A, Cervera R, Font J, et al. Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: Prospective analysis of a series of 92 patients. Clin Exp Rheumatol 1997;15:143.
325. Weidmann CE, Wallace DJ, Peter JB, et al. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol 1988;15:74.
326. Branch DW, Silver R, Pierangeli S, et al. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997;89:549.
327. Loizou S, McCrea JD, Rudge AC, et al. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbentassay (ELISA): Standardization and quantitation of results. Clin Exp Immunol 1985;62:738.
328. Vila P, Hernandez MC, Lopez-Fernandez MF, et al. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994;72:209.
329. Wilson WA. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am 2001;27:499.
330. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000;43:440.
331. Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: Synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001;10:457.
332. Piette JC, Wechsler B, Frances C, et al. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993;20:1802.
333. Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992;166:1318.
334. Balasch J, Carmona F, Lopez-Soto A, et al. Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. Hum Reprod 1993;8:2234.
335. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408.
336. Erkan D, Merrill JT, Yazici Y, et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin. Arthritis Rheum 2001;44:1466.
337. Wahl DG, Bounameaux H, de Moerloose P, et al. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: Do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000;160:2042.
338. Petri M. Hydroxychloroquine: Past, present, future. Lupus 1998;7:65.
339. Petri M. Management of thrombosis in antiphospholipid antibody syndrome. Rheum Dis Clin North Am 2001; 27:633.
340. Lockshin MD. Antiphospholipid antibody syndrome. In: Ruddy S, Harris ED, Sledge CB, eds. Kelly's Textbook of Rheumatology. Philadelphia: W.B. Saunders Company, 2001;1145.
341. Myones BL, McCurdy D. The antiphospholipid syndrome: Immunologic and clinical aspects. Clinical spectrum and treatment. J Rheumatol 2000;27 Suppl 58:20.
342. Baker WF Jr, Bick RL. Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 1999;25:387.
343. Harpaz D, Glikson M, Sidi Y, et al. Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome. Am Heart J 1991;122:1492.
344. Ho YL, Chen MF, Wu CC, et al. Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome. Cardiology 1996;87:354.
345. Jankowski M, Dudek D, Dubiel JS, et al. Successful coronary stent implantation in a patient with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1998;9:753.
346. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993.
347. Derksen RHWM, de Groot PG. Do we know which patients with the antiphospholipid syndrome should receive long-term high dose anti-coagulation? J Autoimmun 2000;15:255.
348. Alarcon-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: A consensus report. Lupus 2003;12:499.
349. al Sayegh FA, Ensworth S, Huang S, et al. Hemorrhagic complications of long-term anticoagulant therapy in seven patients with systemic lupus erythematosus and antiphospholipid syndrome. J Rheumatol 1997;24:1716.
350. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153:1557.
351. Douketis JD, Crowther MA, Julian JA, et al. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. Thromb Haemost 1999;82:1028.
352. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133.
353. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127:177.
354. Della Valle P, Crippa L, Safa O, et al. Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Ann Med Interne (Paris) 1996;147 Suppl 1:10.
355. Bick RL, Rice J. Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: Efficacy and safety-a preliminary report. Clin Appl Thromb Hemost 1999;5 (Suppl 1):S67.
356. Guerin J, Sheng Y, Reddel S, et al. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem 2002;277:2644.
357. Suarez IM, Diaz RA, Aguayo Canela D, et al. Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Lupus 1996;5:81.
358. Alarcon-Segovia D, Sanchez-Guerrero J. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J Rheumatol 1989; 16:1359.
359. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, et al. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. Br J Rheumatol 1997;36:1095.
360. Heilmann L, von Tempelhoff GF, Kuse S. The influence of antiphospholipid antibodies on the pregnancy outcome of patients with recurrent spontaneous abortion. Clin Appl Thromb Hemost 2001;7:281.
361. Shehata HA, Nelson-Piercy C, Khamasta MA. Management of pregnancy in antiphospholipid syndrome. Rheum Dis Clin North Am 2001;27:661.
362. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253.
363. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss-treatment with heparin and low dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584.
364. Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000;183:1008.
365. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119 Suppl:122S.
366. Bick RL. Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: Prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group. Clin Appl Thromb Hemost 2000;6:115.
367. Di Simone N, Caliandro D, Castellani R, et al. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod 1999;14:489.
368. Di Simone N, Ferrazzani S, Castellani R, et al. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum Reprod 1997;12:2061.
369. Silver RK, MacGregor SN, Sholl JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993;169:1411.
370. Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997;337: 148.
371. Spinnato JA, Clark AL, Pierangeli SS, et al. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 1995;172:690.
372. Kaaja R, Julkunen H, Ammala P, et al. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand 1993;72:63.
373. The Pregnancy Loss Study Group. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000;182:122.
374. Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003;48:728.
375. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol 1997;176:1099.
376. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530.
377. Visvanathan S, Scott JK, Hwang KK, et al. Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome. Arthritis Rheum 2003;48:737.
378. Ellis MH, Kesler A, Friedman Z, et al. Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies. Clin Appl Thromb Hemost 2000;6:61.
379. Erkan D, Yazici Y, Harrison MJ, et al. APLASA study: Primary thrombosis prevention in asymptomatic antiphospholipid antibody (APL) patients with low dose aspirin (ASA). Lupus 2002;11:573.
380. Cooper C, Choy E, Arthritis Research Campaign's Clinical Trials Committee. The blossoming of evidence-based clinical rheumatology: The Arthritis Research Campaign's Clinical Trials Collaboration in association with the MRC Clinical Trials Unit, BSR and BOA. Rheumatology 2003;42:713.
381. Finazzi G, Barbui T. Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome:the WAPS project. Provisional Steering Committee of the Warfarin in Antiphospholipid Syndrome (WAPS) Study. Ann Med Interne (Paris) 1996;147 Suppl 1:38.
382. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001;44:2870.
383. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003;48:3272.
384. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: Potential therapeutic applications. Thromb Haemost 1997;78:471.
385. Roubey RAS. New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials, and tribulations. Arthritis Rheum 2003;48:3004.